The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes
Open accessAbstract
Background: The increasing use of mAbs has led to a rise in hypersensitivity reactions (HSRs), which prevent their use as first‐line therapy. HSRs' symptoms, diagnostic tools, and directed management approaches have not been standardized. Objective: We propose a novel evidence‐based classification of HSRs to mAbs, based on the clinical phenotypes, underlying endotypes and biomarkers, as well as their management with desensitization. Methods: Phenotypes, endotypes, and biomarkers of HSRs to 16 mAbs for 104 patients were described and compared with the outcomes of 526 subcutaneous and intravenous desensitizations. Results: Initial reactions presented with 4 patterns: type I–like reactions (63%), cytokine‐release reactions (13%), mixed reactions (21%), and delayed type IV reactions (3%). In contrast, of the 23% breakthrough HSRs during desensitization, 52% were cytokine‐release reactions, 32% were type 1, 12% were mixed, and 4% were type I with delayed type IV. Skin testing to 10 mAbs in 58 patients was positive in 41% of patients. Serum tryptase was elevated in 1 patient and IL‐6 was elevated in 8 patients during desensitization and was associated with a cytokine‐release phenotype. Conclusions: HSRs to mAbs can be defined as type I, cytokine‐release, mixed (type I/cytokine‐release), and type IV reactions, which are identified by biomarkers such as skin test, tryptase, and IL‐6. These phenotypes can be used to improve personalized and precision medicine when diagnosing HSRs to mAbs and providing management recommendations with desensitization. Desensitization provides a safe and effective retreatment option to remain on culprit mAbs as first‐line therapy. GRAPHICAL ABSTRACT Figure. No caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Clinical features and severity grading of anaphylaxis
Brown, S. G. A. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.04.029 · Cited by 1,000
International Con sensus on drug allergy
Demoly, P., Adkinson, N. F., Brockow, K., Castells, M., Chiriac, A. M., Greenberger, P. A., Khan, D. A., Lang, D. M., Park, H. ‐., Pichler, W., et al. (2014) · Allergy · doi:10.1111/all.12350 · Cited by 935
Self-citationBrockow, K., Garvey, L. H., Aberer, W., Atanaskovic‐Markovic, M., Barbaud, A., Bilo, M. B., Bircher, A., Blanca, M., Bonadonna, B., Campi, P., et al. (2013) · Allergy · doi:10.1111/all.12142 · Cited by 813
Castells, M. C., Tennant, N. M., Sloane, D. E., Ida Hsu, F., Barrett, N. A., Hong, D. I., Laidlaw, T. M., Legere, H. J., Nallamshetty, S. N., Palis, R. I., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.044 · Cited by 600
Self-citationTolerability and safety of rituximab (MabThera®)
Kimby, E. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.05.007 · Cited by 470
O'Neil, B. H., Allen, R., Spigel, D. R., Stinchcombe, T. E., Moore, D. T., Berlin, J. D., & Goldberg, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7812 · Cited by 358
Brennan, P. J., Bouza, T. R., Hsu, F. I., Sloane, D. E., & Castells, M. C. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.009 · Cited by 283
Self-citationManaging Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy
Chung, C. H. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0012 · Cited by 278
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies
Sloane, D., Govindarajulu, U., Harrow-Mortelliti, J., Barry, W., Hsu, F. I., Hong, D., Laidlaw, T., Palis, R., Legere, H., Bunyavanich, S., et al. (2016) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2015.12.019 · Cited by 211
Self-citationAdverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
Baldo, B. (2013) · OncoImmunology · doi:10.4161/onci.26333 · Cited by 191
Muraro, A., Lemanske, R. F., Castells, M., Torres, M. J., Khan, D., Simon, H.-U., Bindslev-Jensen, C., Burks, W., Poulsen, L. K., Sampson, H. A., et al. (2017) · doi:10.7892/boris.95346 · Cited by 183
Self-citationO’Meara, S., Nanda, K. S., & Moss, A. C. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000436951.80898.6d · Cited by 160
Sheeley, D. M., Merrill, B. M., & Taylor, L. C. E. (1997) · Analytical Biochemistry · doi:10.1006/abio.1997.2036 · Cited by 152
Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches
Vecillas, L. D. L., Alenazy, L. A., Garcia-Neuer, M. I., & Castells, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061316 · Cited by 143
Self-citationSancho‐Serra, M. D. C., Simarro, M., & Castells, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201040810 · Cited by 141
Self-citationCurrent Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies
Picard, M., & Galvão, V. R. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.12.001 · Cited by 139
Picard, M., Özyiğit, L. P., Caiado, J., Junior, P. F. G.-B., Galvão, V. R., Berlin, S. T., Campos, S. M., Matulonis, U. A., & Castells, M. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.039 · Cited by 132
Self-citationClinical development methodology for infusion‐related reactions with monoclonal antibodies
Doessegger, L., & Banholzer, M. L. (2015) · Clinical & Translational Immunology · doi:10.1038/cti.2015.14 · Cited by 131
Hypersensitivity to Biological Agents—Updated Diagnosis, Management, and Treatment
Galvão, V. R., & Castells, M. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.12.006 · Cited by 122
Self-citationStevens–Johnson syndrome after treatment with rituximab
Lowndes, S. A., Darby, A., Mead, G. M., & Lister, A. T. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf350 · Cited by 120
Mast cell desensitization inhibits calcium flux and aberrantly remodels actin
Ang, W. X. G., Church, A. M., Kulis, M., Choi, H. W., Burks, A. W., & Abraham, S. N. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87492 · Cited by 100
Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies
Hong, D. I., Bankova, L. G., Cahill, K. N., Kyin, T., & Castells, M. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.75 · Cited by 93
Self-citationReactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review
Levin, A. S., Otani, I. M., Lax, T. P., Hochberg, E. P., & Banerji, A. (2016) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.06.022 · Cited by 89
Presentation and Diagnosis of Hypersensitivity to Platinum Drugs
Caiado, J., & Castells, M. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0515-3 · Cited by 79
Self-citationDrug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab
Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Petroni, G., Cammelli, D., Alterini, R., Rigacci, L., Romagnani, S., & Maggi, E. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000336839 · Cited by 69
A review of rituximab in cutaneous medicine
Scheinfeld, N. S. (2006) · Dermatology Online Journal · doi:10.5070/d34ns1k655 · Cited by 57
Thompson, L. M., Eckmann, K. R., Boster, B. L., Hess, K. R., Michaud, L. B., Esteva, F. J., Hortobágyi, G. N., & Barnett, C. M. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0286 · Cited by 54
Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity
Limsuwan, T., & Castells, M. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903446936 · Cited by 39
Self-citationCetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Arnold, D., & Misbah, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc080834 · Cited by 36
González‐de‐Olano, D., Morgado, J. M., Juárez-Guerrero, R., Sánchez‐Muñoz, L., Letéllez-Fernández, J., Malón, D., & Castells, M. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.10.007 · Cited by 31
Self-citation
Cited by
Drug allergy: A 2022 practice parameter update
Khan, D. A., Banerji, A., Blumenthal, K. G., Phillips, E. J., Solensky, R., White, A. A., Bernstein, J. A., Chu, D. K., Ellis, A. K., Golden, D. B. K., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.08.028 · Cited by 563
Marone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555237 · Cited by 62
Brolucizumab and immunogenicity
Sharma, A., Kumar, N., Parachuri, N., Sharma, R., Bandello, F., Kuppermann, B. D., & Loewenstein, A. (2020) · Eye · doi:10.1038/s41433-020-0853-9 · Cited by 51
Drug hypersensitivity in the fast lane
Jakubovic, B. D., Vecillas, L. D. L., Jimenez-Rodriguez, T. W., Sanchez-Sanchez, S., & Castells, M. (2020) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.04.005 · Cited by 33
Self-citationA Systematic Review of Allergen Cross-Reactivity: Translating Basic Concepts into Clinical Relevance
Sharma, E., & Vitte, J. (2024) · Journal of Allergy and Clinical Immunology: Global · doi:10.1016/j.jacig.2024.100230 · Cited by 31
Metadata
- Authors
- Isabwe, G. A. C., Garcia Neuer, M., de las Vecillas Sanchez, L., Lynch, D.-M., Marquis, K., & Castells, M.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 142
- Issue
- 1
- Pages
- 159-170.e2
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2791685657
- Cited by
- 265
- References
- 32
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.